Nifedipine and telmisartan for the treatment of hypertension: the TALENT study

References

• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J.28, 2375–2414 (2007).
   PubMed Web of Science ®Google Scholar
• Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension24, 287–296 (1994).
   PubMed Web of Science ®Google Scholar
• van der Lee R, Kam KL, Pfaffendorf M, van Zwieten PA. Differential time course of the vasodilation action of various calcium antagonists. Fundam. Clin. Pharmacol.12, 607–612 (1998).
   PubMedGoogle Scholar
• Mancia G. The sympathetic nervous system in hypertension. Bjorn Folkow Award Lecture. J. Hypertens.15, 1553–1565 (1997).
   PubMed Web of Science ®Google Scholar
• Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation92, 1326–1331 (1995).
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am. J. Cardiol.80, 1453–1458 (1997).
   PubMed Web of Science ®Google Scholar
• Masuo K, Mikami H, Ogihara T, Tuck ML. Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients. Am. J. Hypertens.10, 600–610 (1997).
   PubMed Web of Science ®Google Scholar
• Terpstra WF, May JF, Smit AJ, de Graeff PA, Crijns HJ. Effects of nifedipine on carotid and femoral arterial wall thickness in previously untreated hypertensive patients. Blood Press. Suppl. (Suppl. 1), 22–29 (2003).
   PubMedGoogle Scholar
• Mancia G, Brown M, Castaigne A et al.; for the INSIGHT Study Group. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension41, 431–436 (2003).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Rosei EA, Bakris GL et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press.14, 196–209 (2005).
   PubMed Web of Science ®Google Scholar
• Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs61, 1501–1529 (2001).
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, D’Angelo A et al. Telmisartan and irbesartan therapy in Type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens. Res.29(11), 849–856 (2006).
   PubMed Web of Science ®Google Scholar
• Derosa G, Fogari E, D’Angelo A et al. Metabolic effects of telmisartan and irbesartan in Type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J. Clin. Pharm. Ther.32(3), 261–268 (2007).
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Ferrari I et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm. Metab. Res.41(12), 893–898 (2009).
   PubMed Web of Science ®Google Scholar
• Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, Type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res.27(7), 457–464 (2004).
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. doi:10.1177/1074248410395018 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM; TALENT investigators. Blood pressure control by the nifedipine GITS–telmisartan combination in patients at high cardiovascular risk: the TALENT study. J. Hypertens.29(3), 600–609 (2011).
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Zoppi A et al. Effect of telmisartan–amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am. J. Hypertens.20(4), 417–422 (2007).
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Bertone G et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with Type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin. Ther.26(8), 1228–1236 (2004).
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Zoppi A et al. Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am. J. Hypertens.18, 577–583 (2005).
   PubMed Web of Science ®Google Scholar
• de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin–angiotensin system. J. Hum. Hypertens.23, 503–511 (2009).
   PubMed Web of Science ®Google Scholar